About PeptideFox
Demystifying peptide research through evidence
Editorial & Medical Review: FoxAI Biomedical Research Team
At PeptideFox, we prioritize intellectual integrity above all else, applying a strict standard to research — always referenced and contextualized. Unlike many other sources of information, we apply equal scrutiny to peer-reviewed, pharmaceutical-sponsored publications as we do to academic mechanistic evidence.
We conduct high-resolution research — which means going beyond polished headline papers and applying scrutiny to claims by extracting and tabulating data from registered clinical trials and supplementary appendices, where critical information on adverse events, phenotype specific responses, and week-by-week data on efficacy and results is often buried.
PeptideFox conducts primary research on real-world-evidence (RWE) of peptides, building off the ground-breaking work on curation and extraction of drug-related entities from public forums by Wang et al. 2026 at Cornell University and Duan & Wei 2025 at the University of Michigan and University of Pennsylvania.
- Lead researcher & data integrity reviewer
- Former McKinsey analyst with extensive experience working with the World Health Organization (WHO) — published in peer-reviewed science journals (BMC Chemistry, Springer Nature) and through the McKinsey Global Institute.
- Clinical & medical reviewer
- Board-certified physician and Assistant Clinical Professor at Michigan State University, holding an M.D. from Georgetown University.
Review date appears only on pages that have gone through the full process of both data-integrity review and medical review.
The State of Medical Research
High-resolution research is an orientation toward applying intellectually honest scrutiny to all research — whether that be pre-clinical academic research or peer-reviewed publications covering clinical trials. While the former is often more straightforward, as the lack of evidence is easier to identify, the latter presents a more complex challenge that requires going beyond the headlines.
"Afflicted by studies with small sample sizes, tiny effects, invalid exploratory analyses, and flagrant conflicts of interest, together with an obsession for pursuing fashionable trends of dubious importance, science has taken a turn towards darkness. As one participant put it, “poor methods get results”. The Academy of Medical Sciences, Medical Research Council, and Biotechnology and Biological Sciences Research Council have now put their reputational weight behind an investigation into these questionable research practices. The apparent endemicity of bad research behaviour is alarming.
In their quest for telling a compelling story, scientists too often sculpt data to fit their preferred theory of the world. Or they retrofit hypotheses to fit their data. Journal editors deserve their fair share of criticism too. We aid and abet the worst behaviours. Our acquiescence to the impact factor fuels an unhealthy competition to win a place in a select few journals. Our love of “significance” pollutes the literature with many a statistical fairy-tale."
For additional information, refer to the work of Marcia Angell — the former editor-in-chief of the New England Journal of Medicine and senior lecturer at Harvard Medical School — who has written about the subject for over a decade in the New York Review of Books and in her 2004 book, The Truth About Drug Companies and John P.A. Ioannidis — the George E. and Lucy Becker Professor of Medicine, Professor of Epidemiology and Population Health and Biomedical Data Science at Stanford University.
Peptides in the Context of Modern Medical Science
Modern medicine is extraordinary at saving your life. Surgery, oncology, infectious disease — when the problem is discrete, single-target interventions work. The regulatory system governing them makes sense.
But living a healthy, functional life is not a discrete problem. Metabolic health, immune regulation, tissue repair, sleep architecture — these are integrated systems. The regulatory framework built for acute care evaluates single drugs targeting single endpoints.
This is not a conspiracy. It is the byproduct of institutional economics and the inertia of a system with a complex web of actors.
FDA approval requires a sponsor willing to fund $1–2 billion in trials. Sponsors invest only when patent protection guarantees returns. Natural peptides — the signaling molecules your body already uses to coordinate repair, metabolism, and immunity — cannot be patented. No rational actor will spend billions to validate a compound competitors can manufacture the next day.
The compounds most mechanistically aligned with human biology are the poorest fit for the economics that govern access to them.
Evidence Landscape of Peptides
Across PeptideFox, we lay out the evidence status of each compound unambiguously. To not do so would violate our core principle of intellectual integrity.
FDA-approved / in pipeline
GLP-1 agonists (semaglutide, tirzepatide), SS-31 (elamipretide), tesamorelin. Established safety profiles. Phase III data for specified trial-populations. Retatrutide is in the FDA pipeline — with approval expected in early 2027.
Extensive human data in academic and/or international research
Thymosin Alpha-1 (approved in 35+ countries), NAD+ precursors (multiple clinical trials, broad clinical use), Vasoactive Intestinal Peptide (multiple Phase II and Phase III trials). As naturally occurring compounds, these lack a path to commercialization through the FDA pipeline.
Emerging
International trials (Thymosin Beta 4, Phase II) and MOTS-c (Phase I)
Pre-clinical
Mechanistic research and pre-clinical data (cell culture, animal models), with strong biological plausibility, but no human trials (KPV, 5-Amino-1MQ). Others with pre-clinical data and limited case study reports by medical doctors (BPC-157). Others from Russia with extensive pre-clinical data (Pinealon), and those corroborated by Western research (Epitalon).
One hedges. One helps inform.
Generalist AIs default to a defensive register on anything pharmacological. FoxAI is built on PeptideFox's research corpus — it returns the structured answer a practitioner would assemble by hand.
$ Does retatrutide cause a HR spike or GI side effects at a low dose?...Probably not a major HR spike orsevere GI at 1 mg — but nobody canguarantee you won’t notice anything. From the clinical data: • Side effects are dose-dependent • 1 mg was the lowest dose studied • HR rise was dose-dependent too → per NEJM 2023 · NEJMoa2301972 At 1 mg weekly: • A mild HR increase is possible • Mild nausea/constipation possible • Severe events are less expected • Individual sensitivity varies To estimate better, tell me: 1. Prior semaglutide / tirzepatide? 2. Your current resting HR? 3. Is 1 mg your first-ever dose?
$ Does retatrutide cause a HR spike or GI side effects at a low dose?...HEART RATE — the thing to watch • Lean, Phase 1: +7.6 bpm at 0.3 mg • Lean, Phase 1: +10.3 bpm at 1 mg • Obese, steady state: +0.7 bpm only • Weight loss resets autonomic tone • Leaner users don’t get that offset GI — typically mild here • GIP ~48% engaged by 1 mg, fast arm • GIP brakes nausea, doesn’t cause it • GLP-1 (nausea driver): only ~7% • Nausea ~14% at 1 mg, near placebo BOTTOM LINE • Gut milder than expected — GIP helps • HR signal is real for leaner bodies • Not a wait-for-high-dose concern
Medical Disclaimer
The content in this site is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.